What’s New and Updates/Changes
The AASLD and IDSA in collaboration with IAS–USA HCV Guidance Panel is seeking an additional community representative to serve on the panel that drafts the Recommendations for Testing, Managing, and Treating Hepatitis C. Community representatives serve a 2 to 3 year term, similar to the scientific panel members, and are expected to serve on at least one subcommittee and to participate actively in all subcommittee and full committee teleconferences. In-person meetings are not expected to occur more than once annually. This is a volunteer position; panel members do not receive a stipend or travel expenses, although assistance with travel may be provided in appropriate circumstances.
Ideal applicants will either have had HCV infection in the past or present, or been active in community organizations representing persons with HCV infection or those at high risk for HCV infection. The chosen applicant must comply with conflict of interest standards of the panel.
Interested individuals should forward a short letter of interest, a curriculum vitae or resume, and a completed conflict of interest disclosure form to: firstname.lastname@example.org by February 15, 2015. Applicants will be screened by a nomination committee and select individuals will be interviewed by phone before final decisions are made.
Additional revisions have been made to Unique Patient Populations: Patients With Decompensated Cirrhosis, sharpening the focus to patients with decompensated cirrhosis only. For guidance on patients with compensated cirrhosis, please refer to Initial Treatment of HCV Infection
The introductory statement of When and In Whom to Initiate Therapy has been revised to reiterate that treatment will benefit almost all patients in all stages of chronic infection and that urgent initiation of therapy is needed in patients with certain conditions.